Bristol Myers Squibb is set to acquire Karuna Therapeutics for $14 billion, valuing Karuna at $330 per share, a 53% premium to its Thursday price. The deal centers on a drug called KarXT, designed to treat schizophrenia. KarXT is under FDA review and, if approved next year, would introduce the first new class of medicines for schizophrenia in decades.
Source link
Bristol Myers to purchase Karuna for $14 billion
